Journal of Cancer Metastasis and Treatment最新文献_第9页

Germline predisposition to soft tissue sarcoma 软组织肉瘤的种系易感性

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.31

J. Vagher, Matthew S. Dietz, J. Schiffman, W. Kohlmann, Luke D Maese

{"title":"Germline predisposition to soft tissue sarcoma","authors":"J. Vagher, Matthew S. Dietz, J. Schiffman, W. Kohlmann, Luke D Maese","doi":"10.20517/2394-4722.2022.31","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.31","url":null,"abstract":"Soft tissue sarcoma (STS) most often occurs sporadically, but can also arise in the setting of a germline cancer predisposition syndrome (CPS). There is significant diversity amongst STS diagnoses as these tumors exhibit a variety of histologies, occur in all age groups, and can occur in any location in the body. This diversity is also reflected in the many known associated germline cancer predisposition associations. Some STS diagnoses, such as anaplastic rhabdomyosarcoma, are associated with high heritability and other STS, such as Ewing sarcoma, are notably absent from known CPS. Recognizing when a STS is more likely to be hereditary can influence clinical management. Individuals diagnosed with STS due to CPS may be at risk for other malignancies and should undergo additional surveillance for early detection. Additionally, family members should undergo genetic testing as they also may be at risk to develop STS and other CPS-associated malignancies. Some underlying cancer predisposition diagnoses may have implications for the treatment of a concurrent malignancy as in the case of PARP inhibitor therapy in the setting of homologous recombination deficiency. This review summarizes current knowledge of selected STS and their associations with CPS.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The role of radiation therapy in the management of primary thymic epithelial neoplasms 放射治疗在原发性胸腺上皮肿瘤治疗中的作用

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.211

C. Johnstone, C. Simone

引用次数: 1

The role of VISTA in the tumor microenvironment VISTA在肿瘤微环境中的作用

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.06

Dina Rabadi, Alia Sajani, R. Noelle, J. Lines

{"title":"The role of VISTA in the tumor microenvironment","authors":"Dina Rabadi, Alia Sajani, R. Noelle, J. Lines","doi":"10.20517/2394-4722.2022.06","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.06","url":null,"abstract":"V-domain Ig Suppressor of T cell Activation (VISTA) is a negative immune checkpoint that is expressed on multiple immune cell subsets and has been characterized in T cells, macrophages, and myeloid-derived suppressor cells. As the only immune checkpoint expressed on naïve T cells, VISTA contributes to the maintenance of T cell quiescence and tolerance. VISTA also regulates multiple myeloid cell activities such as chemotaxis, differentiation, and migration. In the context of cancer, antagonistic monoclonal antibody targeting of VISTA has been shown to aid anti-tumor immunity. Furthermore, combination therapies that include other immune checkpoints such as PD-1 or CTLA-4 with VISTA blockade may enhance therapeutic efficacy in a variety of cancers. Combination therapy may help overcome adaptive resistance to individual checkpoint therapies, thereby improving patient outcomes and survival. Here, we summarize the role of VISTA in myeloid cells and T cells within the tumor microenvironment. We discuss the proposed counter-receptors for VISTA, VISTA antibodies currently in development, and the potential for combination therapies with checkpoint inhibitors such as PD-1 and CTLA-4.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Updates on the pathologic diagnosis and classification of mesothelioma 间皮瘤的病理诊断和分类进展

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.89

J. R. Farkas, M. Sharobim, Jefree J. Schulte

引用次数: 0

The bone marrow niche landscape: a journey through aging, extrinsic and intrinsic stressors in the haemopoietic milieu 骨髓生态位景观:在造血环境中经历衰老、外在和内在压力的旅程

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.166

Antonio Giovanni Solimando, A. Melaccio, A. Vacca, R. Ria

{"title":"The bone marrow niche landscape: a journey through aging, extrinsic and intrinsic stressors in the haemopoietic milieu","authors":"Antonio Giovanni Solimando, A. Melaccio, A. Vacca, R. Ria","doi":"10.20517/2394-4722.2021.166","DOIUrl":"https://doi.org/10.20517/2394-4722.2021.166","url":null,"abstract":"Inflammation and its effects in the bone marrow microenvironment represent a paradigmatic condition in which the hematopoietic niche and the immune systems, thought to properly sustain blood cell production and distinguish between friend and foe, can actively sustain a corrupted neighborhood within a chronic aberrant inflamed state. The bone marrow niche hijacks the physiologic hematopoiesis. The interactions between the hematopoietic stem cells and the niche in the bone marrow are critical determinants of quiescence. We examined several approaches to confront the available evidence; three key points emerged, pointing to the chronic inflammation process, especially the chronic infection and systemic inflammatory states, as leading causes of hematopoietic stem cell depletion. Clonal hematopoiesis, defined as a relative expansion of individual clones, is caused by somatic alterations in essential hematopoietic genes, which increase stem cell fitness. Moreover, terminal differentiation plays a significant role in progenitor loss and inflammatory signaling, promoting clonal selection and clonal hematopoiesis conditions. Specific myeloid malignancies as paradigmatic examples are discussed as a condition associated with inflammation, including the 5q- syndrome, Philadelphia negative myeloproliferative neoplasms, and chronic myeloid leukemia. Aging with increased fitness and hematopoietic stem cell attrition, extrinsic stress, enhanced stressor-specific fitness, and intrinsic defect across the hematopoietic process represent the route for novel insights in defective hematopoiesis. The discussion in this review also points out that the hematopoietic niches’ inflammatory stimulation may affect differentiation patterns and the function of downstream cells.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67651550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM) 克服肿瘤抗原异质性的CAR-T细胞治疗恶性间皮瘤

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.51

Reena R D'Souza, P. Dimou, Reyisa Bughda, E. Hawkins, Clara Leboreiro Babe, A. Klampatsa

引用次数: 1

Molecular pathology of thymoma and thymic carcinoma 胸腺瘤和胸腺癌的分子病理学

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.210

D. Suster, M. K. Basu, A. C. Mackinnon

{"title":"Molecular pathology of thymoma and thymic carcinoma","authors":"D. Suster, M. K. Basu, A. C. Mackinnon","doi":"10.20517/2394-4722.2021.210","DOIUrl":"https://doi.org/10.20517/2394-4722.2021.210","url":null,"abstract":"Thymic epithelial tumors (TETs) comprise a heterogeneous group of epithelial-derived thymic neoplasms with diverse clinical behavior and underlying molecular genetic features. Owing to their rare nature, the molecular classification of TETs has only recently begun to be fully explored. The advent of advanced molecular studies, particularly the ability to sequence the DNA and RNA of tumors in a massively parallel fashion, has led to an increased understanding of the molecular underpinnings of thymic neoplasia. Thymomas, characterized by a heterogeneous group of molecular alterations, tend to have low mutational burdens and various copy number abnormalities including a characteristic loss of chromosomal material in the region of 6q25.2-p25.3, a recurrent, specific point mutation GTF2I p.L424H, and specific expression of certain microRNAs. Thymic carcinomas, in contrast, are generally characterized by increased tumor mutational burdens, multiple copy number alterations, and varied, non-recurrent, somatic mutations. Advances in molecular knowledge of TETs allow for more precise molecular classification of these tumors, and the presence of specific alterations aids in the diagnosis of borderline lesions. In the future, additional molecular studies will better delineate the molecular landscape of these tumors and may one day allow for more targeted treatment algorithms. This review aims to cover the current understanding of the molecular alterations thus far identified in thymomas and thymic carcinomas.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67651806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The safety and efficacy of palbociclib in older patients with advanced breast cancer in a real-world setting 帕博西尼在老年晚期乳腺癌患者中的安全性和有效性

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.64

Etienne Gouton, Tassy Louis, J. Micallef, A. Meskine, R. Sabatier, Maud Cecile-Herry, C. Braticevic, A. Gonçalves, F. Viret, Franck Rouby, F. Rousseau

{"title":"The safety and efficacy of palbociclib in older patients with advanced breast cancer in a real-world setting","authors":"Etienne Gouton, Tassy Louis, J. Micallef, A. Meskine, R. Sabatier, Maud Cecile-Herry, C. Braticevic, A. Gonçalves, F. Viret, Franck Rouby, F. Rousseau","doi":"10.20517/2394-4722.2022.64","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.64","url":null,"abstract":"Aims: Palbociclib has been approved in combination with endocrine therapy (ET) for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), regardless of age. Even though ABC is one of the most prevalent cancers in older patients, very few patients ≥ 65 years old were included in pivotal trials. Therefore, the current study evaluated the safety and efficacy of palbociclib in “real-world” routine treatment of unselected older patients with HR+/HER2- ABC. Methods: Data were collected on patients > 70 years old who were treated with palbociclib plus ET for HR+/HER2- ABC in our institution. We analyzed safety data (CTCAE v4.0 criteria) and outcomes, such as progression-free survival (PFS) and overall survival (OS), as well as any associations between main geriatric characteristics and our results. Furthermore, we assessed safety at a national level by analyzing all palbociclib-related adverse events (AEs) reported in the French Pharmacovigilance Database (FPVD) during the same period. Results: From February 2016 to July 2019, 52 patients were identified with a median age of 80.9 years, of whom 88% presented an AE. The most common grade 3-4 AE was neutropenia (64%). Median PFS and OS were nine months and not reached, respectively. The FPVD reports 227 cases of palbociclib-related AEs, with older and younger patients sharing similar characteristics. Conclusion: Palbociclib is well tolerated in older patients with efficacy comparable to that in younger patients. However, the addition of palbociclib to ET should be evaluated individually in this older and frailer subgroup.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Telemedicine for sarcoma patient care 肉瘤患者护理的远程医疗

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.38

S. Schuetze

引用次数: 0

Tricking the tumour microenvironment into becoming our best rational drug design factory: reversal of immune suppression 诱导肿瘤微环境成为我们最好的合理药物设计工厂:逆转免疫抑制

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.01

M. Ashdown

引用次数: 0